Yellow fever vaccination in HIV-infected patients

HIV Therapy

Volumn 4, Issue 1, 2010, Pages 17-26

  Veit, Olivia ^a   Hatz, Christoph ^b   Niedrig, Matthias ^c   Furrer, Hansjakob ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^c ROBERT KOCH INSTITUTE   (Germany)

Author keywords

17D yellow fever vaccine; Durability; HIV; Immunogenicity; Outbreak; Revaccination; Safety; Serious adverse event; Traveler; Yellow fever

Indexed keywords

17D YELLOW FEVER VACCINE; CD4 ANTIGEN; UNCLASSIFIED DRUG; VACCINE;

ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; MASS IMMUNIZATION; MULTICENTER STUDY; NONHUMAN; WORLD HEALTH ORGANIZATION; YELLOW FEVER;

EID: 74849116505     PISSN: 17584310     EISSN: None     Source Type: Journal    
DOI: 10.2217/hiv.09.52     Document Type: Article

References (40)

1. WHO: Yellow fever vaccine: WHO position paper. Wkly Epidemiol. Rec. 78(40), 349-359 (2003).
2. WHO: Update on progress controlling yellow fever in Africa, 2004-2008. Wkly Epidemiol. Rec. 83(50), 450-458 (2008). ■ Update on control measures of yellow fever in Africa.
3. WHO: Meeting of Global Advisory Committee on Vaccine Safety, 18-19 June 2008. Wkly Epidemiol. Rec. 83(32), 287-292 (2008).
4. Monath TP: Yellow fever: an update. Lancet Infect. Dis. 1(1), 11-20 (2001). ■ Comprehensive overview about yellow fever.
5. Furrer H, Chan P, Weber R, Egger M: Increased risk of wasting syndrome in HIV-infected travellers: prospective multicentre study. Trans. R Soc. Trop. Med. Hyg. 95(5), 484-486 (2001).
6. Veit O, Niedrig M, Chapuis-Taillard C et al.: Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin. Infect. Dis. 48(5), 659-666 (2009). ■■ Largest study published so far concerning the topic, with a comparison of data of HIV-uninfected individuals assessing predictive parameters on immunogenicity to 17DV in HIV-infected patients.
7. Theiler M, Smith HH: The use of yellow fever virus modified by in vitro cultivation for human immunization. Rev. Med. Virol. 10(1), 6-16; discussion 3-5 (2000).
8. Lindsey NP, Schroeder BA, Miller ER et al.: Adverse event reports following yellow fever vaccination. Vaccine 26(48), 6077-6082 (2008).
9. Hayes EB: Acute viscerotropic disease following vaccination against yellow fever. Trans. R Soc. Trop. Med. Hyg. 101(10), 967-971 (2007).
10. Domingo C, Niedrig M: Safety of 17D derived yellow fever vaccines. Expert Opin. Drug Saf. 8(2), 211-221 (2009). ■■ Comprehensive review regarding the safety of 17D yellow fever vaccine, including a list of all reported serious adverse events.
11. Barrett AD, Teuwen DE: Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place? Curr. Opin. Immunol. 21(3), 308-313 (2009).
12. Khromava AY, Eidex RB, Weld LH et al.: Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 23(25), 3256-3263 (2005).
13. Pulendran B, Miller J, Querec TD et al.: Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J. Infect. Dis. 198(4), 500-507 (2008).
14. Cetron MS, Marfin AA, Julian KG et al.: Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm. Rep. 51(RR-17), 1-11; quiz CE1-CE4 (2002).
15. Niedrig M, Lademann M, Emmerich P, Lafrenz M: Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop. Med. Int. Health 4(12), 867-871 (1999). ■ Different assays measuring yellow fever antibodies in HIV-uninfected individuals. Neutralization titer data of these individuals were compared with HIV-infected individuals in [6].
16. Cavassini ML, D'Acremont V, Furrer H, Genton B, Tarr PE: Pharmacotherapy, vaccines and malaria advice for HIV-infected travellers. Expert Opin. Pharmacother. 6(6), 891-913 (2005).
17. Kengsakul K, Sathirapongsasuti K, Punyagupta S: Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J. Med. Assoc. Thai. 85(1), 131-134 (2002). ■ First and only published case of an YF-AND with fatal outcome in an HIV-infected man.
18. Wilson ME, von Reyn CF, Fineberg HV: Infections in HIV-infected travelers: risks and prevention. Ann. Intern. Med. 114(7), 582-592 (1991).
19. Sibailly TS, Wiktor SZ, Tsai TF et al.: Poor antibody response to yellow fever vaccination in children infected with human immunodeficiency virus type 1. Pediatr. Infect. Dis. J. 16(12), 1177-1179 (1997).
20. Receveur MC, Thiebaut R, Vedy S, Malvy D, Mercie P, Bras ML: Yellow fever vaccination of human immunodeficiency virus-infected patients: report of 2 cases. Clin. Infect. Dis. 31(3), E7-E8 (2000).
21. Tattevin P, Depatureaux AG, Chapplain JM et al.: Yellow fever vaccine is safe and effective in HIV-infected patients. AIDS 18(5), 825-827 (2004).
22. Pistone T, Verdière CH, Receveur MH, Ezzedine K, Lafon ME, Malvy D: Immunogénicité et tolérance du vaccin amaril chez le voyageur vivant avec le VIH, France, 2005. BEH Thématique 25-62 (2007).
23. Ho YL, Enohata T, Lopes MH, De Sousa Dos Santos S: Vaccination in Brazilian HIV-infected adults: a cross-sectional STUDY. AIDS Patient Care STDS 22(1), 65-70 (2008).
24. Wallace MR, Brandt CJ, Earhart KC et al.: Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects. Clin. Infect. Dis. 39(8), 1207-1213 (2004).
25. Gunthard HF, Wong JK, Spina CA et al.: Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. J. Infect. Dis. 181(2), 522-531 (2000).
26. Kemper CA, Haubrich R, Frank I et al.: Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients: a double-blind, randomized, placebo-controlled trial. J. Infect. Dis. 187(8), 1327-1331 (2003).
27. Landrum ML, Hullsiek KH, Ganesan A et al.: Hepatitis B vaccine responses in a large US military cohort of HIV-infected individuals: another benefit of HAART in those with preserved CD4 count. Vaccine 27(34), 4731-4738 (2009).
28. Subramaniam KS, Segal R, Lyles RH, Rodriguez-Barradas MC, Pirofski LA: Qualitative change in antibody responses of human immunodeficiency virus-infected individuals to pneumococcal capsular polysaccharide vaccination associated with highly active antiretroviral therapy. J. Infect. Dis. 187(5), 758-768 (2003).
29. Evison J, Farese S, Seitz M, Uehlinger DE, Furrer H, Muhlemann K: Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients. Clin. Infect. Dis. 48(10), 1402-1412 (2009).
30. Falco V, Jordano Q, Cruz MJ et al.: Serological response to pneumococcal vaccination in HAART-treated HIV-infected patients: one year follow-up study. Vaccine 24(14), 2567-2574 (2006).
31. Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K: Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull. World Health Organ. 59(6), 895-900 (1981).
32. Monath TP: Yellow fever vaccine. Expert Rev. Vaccines 4(4), 553-574 (2005). ■■ Comprehensive review of the yellow fever vaccine.
33. Franco-Paredes C, Hidron A, Tellez I, Lesesne J, Del Rio C: HIV infection and travel: pretravel recommendations and health-related risks. Top HIV Med. 17(1), 2-11 (2009).
34. WHO: Yellow fever in Africa and South America, 2007. Wkly Epidemiol. Rec. 84(13), 97-104 (2009).
35. CDC: Chapter 5. Yellow fever vaccine requirements and information on malaria risk and prophylaxis, by country. CDC Travellers' Health Yellow Book. wwwn.cdc.gov/travel/yellowbook/ch5/malaria-yellow-fever-table.aspx Overview of the yellow fever vaccination requirements by country.
36. UNAIDS. Report on the global AIDS epidemic. www.unaids.org/en/ KnowledgeCentre/HIVData/GlobalReport/2008/2008-Global-report.asp (Accessed 14 April 2009) Report on the global AIDS epidemic. According to this report, HIV-prevalence in yellow fever-endemic countries was estimated in regard to the countries considered by CDC [101] to have endemic yellow fever.
37. Veit O: Assessment of immunogenicity and safety of yellow fever vaccination in HIV-infected patients, a pilot study. Swiss Tropical Institute, University of Basel, Basel (2006). www.sti.ch/fileadmin/user-upload/Pdfs/tnt/ Abstract-Veit.pdf
38. WHO. Health topics: yellow fever. www.who.int/topics/yellow-fever/en/
39. CDC. Traveler's Health: yellow book. Chapter 2: yellow fever. wwwnc.cdc.gov/travel/yellowbook/2010/chapter-2/yellow-fever.aspx
40. WHO. International travel and health interactive map. http://apps.who.int/tools/geoserver/www/ith/index.html